Atlantic Healthcare Completes Phase 3 Trial Enrollment for Alicaforsen as Pouchitis Treatment

Atlantic Healthcare Completes Phase 3 Trial Enrollment for Alicaforsen as Pouchitis Treatment
Atlantic Healthcare has completed enrollment for a Phase 3 trial evaluating the safety and efficacy of alicaforsen in patients with pouchitis, a frequent complication after surgery to treat different forms of inflammatory bowel disease (IBD). IBD patients have increased production of ICAM-1 protein, which correlates with intestinal inflammation. Alicaforsen binds specifically to the human ICAM-1 messenger RNA, reducing the amount of ICAM-1 protein that is produced, thus helping to stop the disease-associated inflammation. Launched in August 2015, the randomized, multicenter, double-blind, placebo-controlled trial (NCT02525
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *